BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 18, 2010
View Archived Issues
Novel Erk/PI3K inhibitors with potent preclinical activity described by AEterna Zentaris
Read More
AIN-457 evaluated in clinical studies in patients with noninfectious uveitis
Read More
Low efficacy seen with FMP2.1/AS02A malaria vaccine in children
Read More
Novel c-Met inhibitors claimed by Vertex
Read More
Kalypsys claims novel glucose-dependent insulinotropic receptor (GPR119) ligands
Read More
Novel M1 receptor allosteric modulators disclosed by Merck & Co.
Read More
Novel AMPK activators disclosed by Merck & Co. and Metabasis
Read More
ArQule presents preclinical data on novel Raf kinase B and C inhibitors
Read More
LA-480 inhibits HGF-dependent and independent c-Met signaling in preclinical study
Read More
Phase II safety/efficacy data on anti-IP-10 antibody in subjects with active UC presented
Read More
CR-2017 improves intestinal activity/tolerance in functional gut disorders patients
Read More
Italy approves use and reimbursement of afamelanotide for erythropoietic protoporphyria
Read More
Concert Pharmaceuticals claims novel deuterated NS3 protease inhibitors
Read More
Aastrom treats first patient in phase II tissue repair cell trial in dilated cardiomyopathy
Read More
Phase III data point to efficacy of pirfenidone in idiopathic pulmonary fibrosis
Read More
FDA sets Zenvia PDUFA date for October 2010
Read More
ViroPharma presents final open-label data for Cinryze
Read More
ARCA agrees on SPA with FDA for bucindolol study in genotype-defined heart failure
Read More
Hemispherx Biopharma plans for phase II Ampligen trials in China
Read More
Bristol-Myers Squibb: Q1 product and pipeline update
Read More
Encouraging preliminary safety results from phase II trial of pixantrone reported
Read More
Emergent to commence phase I trial of anthrax monoclonal antibody
Read More
Novel oncolytic virus NTX-010 studied for SCLC in new phase II trial
Read More
FDA issues complete response letter for roflumilast
Read More
PEARL II study of Esmya meets primary efficacy and safety endpoints
Read More
Inhibitex initiates clinical trials of INX-189 in HCV infections
Read More
ATX-MS-1467 begins second phase I study in MS
Read More